Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 17 Source: CRO
- €981.7 million turnover
-
€272.6 million
profit - 615 employees
-
31st Dec 16 Source: CRO
- €1.3 billion turnover
-
€99.5 million
profit - 588 employees
- 10 more years available »
Ranking
By Turnover
(€981.7 million)- 88th in Top Companies
- 12th in Pharma
By Employees
(615)- 302nd in Top Companies
- 26th in Pharma
-
- 615
- €981.7 million
Employees
- Ruth Beadle General Manager
Latest News
- 5:11pm Trinity Biotech reports drop in revenues as it books €5.1m tax charge
- 4:00pm Facebook to allow users control data websites share with social network
- 2:57pm Belgian Ryanair unions tell members to refuse to staff flights hit by Portuguese strike
- 1:21pm Chinese FDI to Ireland jumps 75% as it bucks global trend
- 1:00pm Ryanair counsel says pilots’ position on 2018 agreement is ‘extraordinary’